| Literature DB >> 35710416 |
Yuan Wang1, Cheng-Cheng Tian2, Yun-Yun Jiao1, Min-Rui Liu3, Xue-Shan Ma1, Hai-Xia Jin1, Ying-Chun Su1, Xiang-Yang Zhang1, Wen-Bin Niu1, Gui-Don Yao1, Wen-Yan Song4.
Abstract
BACKGROUND: Nonobstructive azoospermia (NOA) is one of the most difficult forms of male infertility to treat, and its pathogenesis is still unclear. miRNAs can regulate autophagy by affecting their target gene expression. Our previous study found that miR-188-3p expression in NOA patients was low. There are potential binding sites between the autophagy gene ATG7 and miR-188-3p. This study aimed to verify the binding site between miR-188-3p and ATG7 and whether miR-188-3p affects autophagy and participates in NOA by regulating ATG7 to influence the autophagy marker genes LC3 and Beclin-1.Entities:
Keywords: ATG7; Autophagy; Nonobstructive azoospermia; miR-188-3p
Mesh:
Substances:
Year: 2022 PMID: 35710416 PMCID: PMC9202134 DOI: 10.1186/s12958-022-00951-0
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 4.982
The clinical information of patients whose testis tissue collected in the reproductive medicine center(x ± s)
| Index | NOA group | Control group | |
|---|---|---|---|
| Age (years) | 27.25 ± 3.61 | 29.50 ± 5.03 | 0.233 |
| FSH (IU/L) | 21.30 ± 6.86* | 5.13 ± 2.94 | 0.000 |
| LH (IU/L) | 10.44 ± 4.34* | 4.64 ± 1.92 | 0.000 |
| T (ng/ml) | 3.27 ± 2.39 | 4.60 ± 2.12 | 0.053 |
| PRL (ng/ml) | 12.65 ± 4.82 | 9.91 ± 4.26 | 0.254 |
| E2 (pg/ml) | 20.59 ± 13.68 | 26.55 ± 9.10 | 0.143 |
| P (ng/ml) | 0.50 ± 0.27 | 3.11 ± 9.31 | 0.877 |
| Left testis volume (ml) | 7.44 ± 1.93* | 13.44 ± 3.85 | 0.000 |
| Right testis volume (ml) | 8.00 ± 2.66* | 13.44 ± 3.85 | 0.000 |
| Number of patients with abnormal secondary sexual characteristics no./total no. (%) | 0/16 (0) | 0/16 (0) | 1.000 |
| Number of patients with varicocele no./total no. (%) | 0/16 (0) | 0/16 (0) | 1.000 |
| Number of patients with genital abnormalities no./total no. (%) | 0/16 (0) | 0/16 (0) | 1.000 |
| Number of patients with abnormal karyotype no./total no. (%) | 0/16 (0) | 0/16 (0) | 1.000 |
| Number of patients with Y chromosome microdeletions no./total no. (%) | 0/16 (0) | 0/16 (0) | 1.000 |
Plus–minus values are means ± SD. To convert values for estradiol to picomoles per liter, multiply by 3.671. To convert values for testosterone to nanomoles per liter, multiply by 3.467
Explanation for the relevant abbreviations:
FSH means Follicle-stimulating hormone, LH means Luteinizing hormone, T means Total testosterone, PRL means prolactin, E2 means Estradiol and P means Prog
*Statistically significant difference compared with control group (P < 0.05)
The clinical information of patients whose pathological sections in the pathology department(x ± s)
| Index | NOA group ( | Control group ( | |
|---|---|---|---|
| Age (years) | 31.20 ± 4.87 | 28.40 ± 8.79 | 0.292 |
| FSH (IU/L) | 21.53 ± 9.67* | 6.46 ± 1.25 | 0.009 |
| LH (IU/L) | 12.00 ± 5.79* | 3.59 ± 0.52 | 0.009 |
| T (ng/ml) | 2.99 ± 0.40 | 4.36 ± 1.26 | 0.075 |
| PRL (ng/ml) | 10.97 ± 3.05 | 8.89 ± 1.50 | 0.116 |
| E2 (pg/ml) | 21.13 ± 6.4 | 30.16 ± 7.32 | 0.076 |
| P (ng/ml) | 0.25 ± 0.11 | 0.42 ± 0.20 | 0.059 |
| Left testis volume (ml) | 6.40 ± 1.67* | 12.80 ± 2.95 | 0.014 |
| Right testis volume (ml) | 6.40 ± 1.67* | 12.80 ± 2.95 | 0.014 |
| Number of patients with abnormal secondary sexual characteristics no./total no. (%) | 0/5 (0) | 0/5 (0) | 1.000 |
| Number of patients with varicocele no./total no. (%) | 0/5 (0) | 0/5 (0) | 1.000 |
| Number of patients with genital abnormalities no./total no. (%) | 0/5 (0) | 0/5 (0) | 1.000 |
| Number of patients with abnormal karyotype no./total no. (%) | 0/5 (0) | 0/5 (0) | 1.000 |
| Number of patients with Y chromosome microdeletions no./total no. (%) | 0/5 (0) | 0/5 (0) | 1.000 |
Plus–minus values are means ± SD. To convert values for estradiol to picomoles per liter, multiply by 3.671. To convert values for testosterone to nanomoles per liter, multiply by 3.467
Explanation for the relevant abbreviations:
FSH means Follicle-stimulating hormone, LH means Luteinizing hormone, T means Total testosterone, PRL means prolactin, E2 means Estradiol and P means Prog
*Statistically significant difference compared with control group (P < 0.05)
Fig. 1The results of high-throughput sequencing and expression and localization of the ATG7 gene in the testis. A The results of differentially expressed genes in high-throughput sequencing analysis between NOA patients and patients with normal spermatogenesis (n = 3). B-C In the patients with NOA, the expression levels of the ATG7 gene (B) and protein (C) were higher than the expression levels of the ATG7 gene in the control group, as detected by qRT-PCR and Western blotting. D ATG7 protein staining was brownish yellow and was localized in the cytoplasm of spermatogenic cells at all levels. *Statistically significant difference compared with the control group (P < 0.05)
IOD analysis of ATG7 protein expression in testis tissues of each group
| Group | n | IOD | |
|---|---|---|---|
| Control group | 20 | 47.070 ± 4.7515 | 0.000 |
| NOA group | 20 | 105.120 ± 8.0311 |
Fig. 2The effect of miR-188-3p overexpression or inhibition on ATG7 expression and the verification of their interaction sites. A ATG7 gene expression after overexpression/inhibition of miR-188-3p was significantly lower/higher than the ATG7 gene expression in the control group. B The expression of ATG7 protein in the miR-188-3p mimic group was lower than the expression of ATG7 protein in the control group, as detected by Western blot. C The expression of ATG7 protein in the miR-188-3p inhibitor group was higher, as detected by Western blot. D The mutual binding sites between miR-188-3p and ATG7 were predicted. E The ATG7 3'-UTR wild-type (WT) plasmids and mutant (MUT) plasmids were constructed and sequenced as dual luciferase reporter. F miR-188-3p expression after miR-188-3p overexpression/inhibition was significantly higher/lower than the miR-188-3p expression in the control group. G The luciferase activity of ATG7 3'-UTR WT was lower in the miR-188-3p mimic group than in the miR-188-3p mimic NC group. There was no significant difference in MUT luciferase activity between the two groups. *Statistically significant difference compared with the control group (P < 0.05)
Fig. 3The expression of LC3 and Beclin-1 and the localization of LC3 in testicular tissue. The LC3 protein was localized mainly in the cytoplasm of spermatogenic cells at all levels, showing a brownish yellow colour. The LC3 protein level in NOA patients was elevated in comparison with the LC3 protein level in the control group. B-C LC3 (B) and Beclin-1 (C) gene expression levels in the NOA group were enhanced. D-E LC3 (D) and Beclin-1 (E) protein expression levels in the NOA group were higher than the levels in the control group. *Statistically significant difference compared with the control group (P < 0.05)
IOD analysis of LC3 protein expression in testis tissues of each group
| Group | n | IOD | |
|---|---|---|---|
| Control group | 5 | 39.478 ± 4.473 | 0.009 |
| NOA group | 5 | 76.241 ± 4.213 |
Fig. 4The effect of miR-188-3p overexpression or inhibition on autophagy. A-B LC3 (A) and Beclin-1 (B) gene expression in the miR-188-3p mimic group was lower than the LC3 and Beclin-1 gene expression in the miR-188-3p mimic NC group. C LC3 II protein in the miR-188-3p mimic group was decreased. D-E LC3 (D) and Beclin-1 (E) gene expression in the miR-188-3p inhibitor group was higher than the LC3 and Beclin-1 gene expression in the miR-188-3p mimic NC group. F Beclin-1 protein in the miR-188-3p mimic group was decreased. G The degree of punctate aggregation of LC3 decreased in the miR-188-3p mimic group and increased in the miR-188-3p inhibitor group. DAPI fluorescence is shown in blue, and LC3 II fluorescence is shown in green. White arrows mark LC3 II fluorescence. H The number of autophagosomes in the miR-188-3p mimic group was alleviated. Red arrows mark autophagosomes. *Statistically significant difference compared with the control group (P < 0.05)